Bristol-Myers to license two of its drugs to Biogen, Roche

Bristol-Myers to license two of its drugs to Biogen, Roche

Bristol-Myers Squibb Co said on Thursday it entered into a deal with Biogen Inc and Roche Holding AG to license two of its drugs for an upfront fee of $470 million. Bristol will license its experimental neurodegenerative disorder drug, BMS-986168, to Biogen for use in progressive supranuclear palsy, which is characterized by brain cell damage.

from Biotech News